TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11782640

Group type: EXPERIMENTAL
Intervention: Chronic ACL deficient patients
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ACL reconstructed patients
Number of subjects: 81

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 81

Group type: COMPARATOR
Intervention: Acute ACL deficient subjects
Number of subjects: 81
Study: 9793664

Group type: COMPARATOR
Intervention: Isoflurane-N2O anaesthesia during upper abdominal surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane-N2O anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane-N2O-fentanyl anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (prostaglandin E1 before surgical incision)
Number of subjects: 30
Study: 8291119

Group type: EXPERIMENTAL
Intervention: CD8+ cell-depleted bone marrow
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unmodified bone marrow (Control)
Number of subjects: 38
Study: 15904653

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of Ramipril and Telmisartan
Number of subjects: 37
Study: 31759587

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Whipped cream
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sour cream
Number of subjects: 47
Study: 30658932

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study: 28934792

Group type: EXPERIMENTAL
Intervention: CCPRF
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CRF
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 43
Study: 25220488

Group type: EXPERIMENTAL
Intervention: Home Exercise Program (HEP)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 390
Study: 23130675

Group type: EXPERIMENTAL
Intervention: T+5-HT(1A)ra
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: T+PDE5i
Number of subjects: 54
Study: 20947917

Group type: EXPERIMENTAL
Intervention: Over-the-head CPR
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lateral CPR
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Alternating CPR
Number of subjects: 102
Study: 18555224

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Endometrin 100 mg twice a day, n = 12; Endometrin 100 mg three times a day, n = 11; Crinone 8% gel 90 mg every day, n = 17)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intramuscular (IM) progesterone (50 mg every day, n = 200)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intramuscular (IM) progesterone
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Vaginal and IM progesterone
Number of subjects: 240
Study: 17214405

Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg/day for 21 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (cellulose tablets)
Number of subjects: 20
Study: 12766655

Group type: EXPERIMENTAL
Intervention: Parasacral approach with 20 ml ropivacaine, 0.75% (single bolus)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Winnie's single injection approach with 20 ml ropivacaine, 0.75% (single bolus)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Winnie's double injection approach with 20 ml ropivacaine, 0.75% (10 ml plus 10 ml)
Number of subjects: 150
Study: 10660713

Group type: EXPERIMENTAL
Intervention: Porous coated Osteonic 7000 tibial component (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard saw blade with the same tibial component as Group 1 (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated Osteonic tibial component (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite Duracon tibial component (Group 4)
Number of subjects: 60
Study: 9249622

Group type: EXPERIMENTAL
Intervention: Patients with visual hallucinations (VH)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Patients without visual hallucinations (Control)
Number of subjects: 29
Study: 8262828

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) at a dose of 25 Gy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intraoperative radiotherapy (IORT) at a dose of 20 Gy or less
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined treatment of IORT and modified total esophagectomy
Number of subjects: 62
Study: 3553433

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg (t.i.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (t.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (t.i.d.)
Number of subjects: 10
Study: 29522132

Group type: EXPERIMENTAL
Intervention: Co-occurrence among IG predators in experimental plots of maize and soybean.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-occurrence among aphid predators on tansy (using published data).
Number of subjects: 0
Study: 27504925

Group type: EXPERIMENTAL
Intervention: Immediate computerized brief intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed computerized brief intervention
Number of subjects: 80
Study: 24636210

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily
Number of subjects: 497

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily (T-scores < -2.0)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily (T-scores < -2.0)
Number of subjects: 497
Study: 23142059

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone
Number of subjects: 512
Study: 20404221

Group type: EXPERIMENTAL
Intervention: Bosentan 250 mg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg daily
Number of subjects: 10
Study: 18317680

Group type: EXPERIMENTAL
Intervention: Sourdough bread (leavened for 8 hours with autochthonous Saccharomyces cerevisiae and bacilli)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reference bread (leavened for 2 hours with commercial baker yeast)
Number of subjects: 16
Study: 15990081

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% fixed combination (Trav/Tim)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Travoprost 0.004% (Trav)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Timolol 0.5% (Tim)
Number of subjects: 263
Study: 12612224

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10475291

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in 75% N2O/O2 (VC)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Propofol 2‐mg/kg bolus (i.v.)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both VC and i.v. groups
Number of subjects: 56
Study: 7815223

Group type: EXPERIMENTAL
Intervention: Heparin-bonded catheter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thrombosis presence
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasound-proved thrombosis
Number of subjects: 50
Study: 2046141

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-beta group (control)
Number of subjects: 48
Study: 6269688

Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30683147

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 480

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: All groups (Electro-acupuncture, Manual acupuncture, Sham acupuncture)
Number of subjects: 480
Study: 27866765

Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: SA4Ag and SA3Ag vaccines
Number of subjects: 284
Study: 25382371

Group type: EXPERIMENTAL
Intervention: Vertical two-thumb technique (VTT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Two-thumb encircling technique (TTE)
Number of subjects: 36
Study: 23507066

Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 34
Study: 20877395

Group type: EXPERIMENTAL
Intervention: Combination treatment with 4 g of omega-3 fatty acids and 20 mg of simvastatin daily for 6 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Simvastatin monotherapy of 20 mg daily for 6 weeks
Number of subjects: 62
Study: 19359718

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Toremifen 240 mg/day
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Toremifen 60 mg/day
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Letrozol 2.5 mg/day
Number of subjects: 451
Study: 17522508

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) mapping with ultrastaging using pan‐cytokeratin IHC and standard histopathology
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard histopathologic evaluation
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) mapping excluding cell aggregates ≤0.2 mm
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Evaluation of H&E stained step sections of SLNs
Number of subjects: 161
Study: 15372353

Group type: EXPERIMENTAL
Intervention: Counselling by GPs
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: GPs' assessment of intervention practicability
Number of subjects: 551
Study: 15111631

Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 65
Study: 10612572

Group type: EXPERIMENTAL
Intervention: Chronic airway diseases (purulent sputum)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Chronic airway diseases (mucoid sputum)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal subjects (induced sputum)
Number of subjects: 59
Study: 7492129

Group type: EXPERIMENTAL
Intervention: 5% doxepin cream
Number of subjects: 309

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 309
Study: 2049230

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) infused over 60 min at a dosage of 1.5 x 10(6) i.u.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anistreplase infused over 5 min at a dosage of 30 units
Number of subjects: 24
Study: 6791393

Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition (2 g CH/kg b.w.)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Basic nutrition (5 g CH/kg b.w.)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sole AA-substitution (1 g AA/kg b.w.)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-fed control group
Number of subjects: 47
Study: 31713753

Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with conventional swallowing therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS combined with conventional swallowing therapy
Number of subjects: 28
Study: 30625179

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6g/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Energy Drink (250 ml containing 80 mg caffeine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol mixed with Energy Drink (AMED)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30134942

Group type: EXPERIMENTAL
Intervention: Acupuncture and routine care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mosapride citrate and routine care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 120
Study: 26802811

Group type: EXPERIMENTAL
Intervention: Supportive‐Expressive Dynamic Psychotherapy (SEDP)
Number of subjects: 46
Study: 25143722

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: COPD-smokers
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: COPD-ex-smokers
Number of subjects: 43

Group type: COMPARATOR
Intervention: Smokers with normal lung function
Number of subjects: 43
Study: 22284563

Group type: EXPERIMENTAL
Intervention: Early ibuprofen treatment (n = 54)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Expectant management (blinded placebo, n = 51)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study: 20417243

Group type: EXPERIMENTAL
Intervention: High food intake frequency with MTHFR C677CC genotype
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High food intake frequency with MTHFR C677CT genotype
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High food intake frequency with MTHFR C677TT genotype
Number of subjects: 200
Study: 17620075

Group type: EXPERIMENTAL
Intervention: Grazax (75,000 SQ-T, sublingual immunotherapy tablet)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study: 15790610

Group type: EXPERIMENTAL
Intervention: B-group vitamins (vitamin B1, 250 mg; vitamin B6, 250 mg; vitamin B12, 1000 microg twice daily) plus metformin (850 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Folic acid (174 microg twice daily) plus metformin (850 mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 60
Study: 11932303

Group type: EXPERIMENTAL
Intervention: 20 mg pegvisomant
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Longitudinal open-label pegvisomant treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9804648

Group type: EXPERIMENTAL
Intervention: Remacemide (up to 150 mg every 6 hours)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Remacemide
Number of subjects: 171
Study: 7752668

Group type: EXPERIMENTAL
Intervention: β-blockers (e.g., bisoprolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers (post-MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0
Study: 30383918

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin
Number of subjects: 13
Study: 31047298

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab therapy (monthly or pro re nata)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Baseline BCVA
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: OCT features (horizontal extension of IRF, SRF, PED)
Number of subjects: 614
Study: 27832073

Group type: EXPERIMENTAL
Intervention: 25 μmoles sulforaphane daily for four weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 150 μmoles sulforaphane daily for four weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: All groups (sulforaphane and placebo)
Number of subjects: 89
Study: 24852515

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GLP-1 analogue (exenatide)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 22050496

Group type: EXPERIMENTAL
Intervention: lornoxicam (group L, n=32 patients)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: paracetamol (group P, n=31 patients)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: tramadol with patient‐controlled analgesia (group T, n=32 patients)
Number of subjects: 95
Study: 19240980

Group type: EXPERIMENTAL
Intervention: Hip protector pads
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 17076696

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15153710

Group type: EXPERIMENTAL
Intervention: rHuEPO (epoetin-alpha) 150 IU/kg subcutaneously three times a week for a minimum of 12 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: rHuEPO treatment
Number of subjects: 10
Study: 11426506

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 635

Group type: COMPARATOR
Intervention: Crossover treatment (alternate medication)
Number of subjects: 635
Study: 9470828

Group type: EXPERIMENTAL
Intervention: PCI 36 Gy in 18 daily fractions
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: PCI 24 Gy in 12 fractions
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: PCI (most commonly used regimens: 30 Gy in 10 fractions and 8 Gy in a single dose)
Number of subjects: 314

Group type: COMPARATOR
Intervention: No PCI
Number of subjects: 314
Study: 8186313

Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Immediate appendicectomy
Number of subjects: 100
Study: 3154311

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study: 31765263

Group type: EXPERIMENTAL
Intervention: Nivolumab, 3 mg/kg every 2 weeks for the first 4 cycles, then 480 mg every 4 weeks after cycle 4, administered intravenously.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 42
Study: 29083249

Group type: EXPERIMENTAL
Intervention: Fresh Start program
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 1083
Study: 26935273

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC) with the Watchman device
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Registry study LAAC
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC)
Number of subjects: 110
Study: 26115442

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 14 muscle pairs MRC scale
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Neuropathy Impairment Scale motor‐subset
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Self‐evaluation scale
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MMN‐RODS© (Rasch‐built overall disability scale)
Number of subjects: 26
Study: 23843473

Group type: EXPERIMENTAL
Intervention: Nordic diet (ND)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 166
Study: 20936979

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule (vaccines at 0, 1, and 2 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard vaccination schedule (vaccines at 0, 1, and 6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall drug users on accelerated schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall drug users on standard schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completion of the vaccination schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seroprotection at 6 months for accelerated schedule
Number of subjects: 0
Study: 18760649

Group type: EXPERIMENTAL
Intervention: 16 Gy boost dose after complete lumpectomy
Number of subjects: 5569

Group type: COMPARATOR
Intervention: 0 Gy boost dose after complete lumpectomy
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: 26 Gy boost dose after incomplete lumpectomy
Number of subjects: 5569

Group type: COMPARATOR
Intervention: 10 Gy boost dose after incomplete lumpectomy
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: 16 Gy boost dose
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: 10 Gy boost dose
Number of subjects: 5569

Group type: COMPARATOR
Intervention: 0 Gy boost dose
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: 26 Gy boost dose
Number of subjects: 5569
Study: 15701299

Group type: EXPERIMENTAL
Intervention: Maintenance interferon therapy
Number of subjects: 2700000

Group type: EXPERIMENTAL
Intervention: Alternative medical strategies to reduce hepatic fibrosis
Number of subjects: 2700000
Study: 14972006

Group type: EXPERIMENTAL
Intervention: Day surgery program
Number of subjects: 204
Study: 10066694

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (4 x 5 g/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8721127

Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine suppository (BN)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine suppository (BN) and 50 mg indomethacine suppository (IND)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine suppository (BN) and 50 mg diclofenac suppository
Number of subjects: 56

Group type: COMPARATOR
Intervention: No suppository (control group)
Number of subjects: 56
Study: 1867231

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and calcium antagonists
Number of subjects: 0
Study: 7066141

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg/70 kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 30
Study: 31400518

Group type: EXPERIMENTAL
Intervention: SurvivorLink (patient-controlled electronic personal health record)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 20
Study: 30591094

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillatory (HFCWO)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine clapping (Control)
Number of subjects: 90
Study: 27580060

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Non nucleoside reverse transcription inhibitor-based ART
Number of subjects: 129
Study: 25257518

Group type: EXPERIMENTAL
Intervention: Smartphone- and internet-enabled Parkinson's tracker smartphone app
Number of subjects: 222

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 222